Jeff Yass’s Centessa Pharmaceuticals CNTA Stock Holding History

Jeff Yass’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-17,737	Closed	-$705K	–	13514
2026 Q1	$705K	Buy	17,737 +6,174	+53%	+$158K	﹤0.01%	8799
2025 Q4	$289K	Buy	+11,563	New	+$293K	﹤0.01%	10035
2025 Q2	–	Sell	-899,505	Closed	-$11.4M	–	12768
2025 Q1	$12.9M	Buy	899,505 +883,759	+5,613%	+$14.5M	﹤0.01%	2216
2024 Q4	$264K	Sell	15,746 -12,138	-44%	-$201K	﹤0.01%	10108
2024 Q3	$446K	Buy	+27,884	New	+$342K	﹤0.01%	8744
2023 Q2	–	Sell	-12,616	Closed	-$48.6K	–	12184
2023 Q1	$48.6K	Buy	+12,616	New	+$46.2K	﹤0.01%	11709

Jeff Yass's CNTA Position: Q2 2026 in Review

Jeff Yass sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 17,737 shares — an estimated $705K sold.

Jeff Yass first reported a position in CNTA in Q1 2023 and held it in 6 quarters. The position peaked at $12.9M in Q1 2025. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

Jeff Yass reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Jeff Yass sold 17,737 Centessa Pharmaceuticals shares in Q2 2026, an estimated $705K.
Jeff Yass first reported a position in Centessa Pharmaceuticals in Q1 2023 and held it in 6 quarters.
Jeff Yass's Centessa Pharmaceuticals position peaked at $12.9M in Q1 2025.
0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.